Skip to main content
OpenTrials
Completed

NCT Number: NCT01691742

MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery

A. Purpose To compare MiraLAX versus placebo for preventing constipation in the immediate postoperative period following pelvic reconstructive surgery in women taking routine docusate sodium.

B. Objectives

1. Specific Aims Specific Aim 1: To compare time to first bowel movement (BM) between MiraLAX versus placebo in women receiving routine docusate sodium after pelvic reconstructive surgery.

Specific Aim 2: To compare patient reported outcomes of BM quality and associated gastrointestinal (GI) symptoms between MiraLAX versus placebo using the Bristol stool scale and the validated Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) in women receiving routine docusate sodium after pelvic reconstructive surgery.

Specific Aim 3: To evaluate GI-related quality of life between MiraLAX versus placebo utilizing the validated Patient Assessment of Constipation Quality-of-Life Questionnaire (PAC-QOL) in women receiving routine docusate sodium after pelvic reconstructive surgery. 2. Hypotheses The investigators hypothesize that MiraLAX will optimally prevent constipation following pelvic reconstructive surgery by decreasing time to first BM, decreasing GI symptoms associated with constipation, and increasing measures of GI-related quality of life, while minimizing the bothersome side effects associated with stimulant laxatives.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Post Procedural Constipation

Age range

19 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Duke University, Department of Urogynecology

Durham, North Carolina, 27707, United States

About this study

This is a randomized double-blind placebo-controlled clinical trial of MiraLAX versus placebo in women undergoing pelvic reconstructive surgery receiving routine docusate sodium. Subjects will be screened for eligibility during their preoperative visits and once enrolled, they will be randomized to receive MiraLAX or placebo starting on postoperative day (POD) 1 and continuing through POD 5. Subjects will be instructed to stop taking this medication if they experience any diarrhea. Subjects in both arms will be instructed to take milk of magnesia as a rescue laxative if they do not experience a BM by the morning of POD 6. All subjects will be provided a 30 day supply of docusate sodium and be instructed to begin this medication on POD 1.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • English-speaking female patients
  • > 18 years of age
  • Not pregnant (patients of childbearing potential will have a serum pregnancy test done pre-operatively as part of their surgical planning)
  • Undergoing surgery for pelvic organ prolapse or stress urinary incontinence
  • Recruited from the Duke University Division of Urogynecology

Exclusion criteria

  • Allergy/hypersensitivity to study medications
  • Cardiac or renal disease
  • Takes chronic daily laxatives
  • Excluded if unable to complete at least 5 days of a 7 day baseline bowel diary
  • Excluded if mesh resection or Interstim procedure
  • Excluded if concurrent surgery includes anal sphincteroplasty or rectovaginal fistula repair

Treatment and study plan

MIRALAX

Drug

MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery

Other names: PEG 3350, Polyethylene Glycol 3350

Placebo

Drug

Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery

Other names: Maltodextrin

Rescue Laxative

Drug

All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.

Other names: Milk of Magnesia

Primary outcomes

  1. Time to first postoperative bowel movement

    Time frame: First postoperative week

    The primary outcome is time to first postoperative bowel movement (in hours, converted to days) based upon postoperative bowel diary. Time will be calculated based upon date and time of first postoperative bowel movement from start time of surgery.

Secondary outcomes

  1. Other postoperative medication use

    Time frame: First postoperative week

    Rescue laxative use, daily pain level and narcotic use will be obtained from postoperative bowel diaries.

  2. Evaluation of symptoms and quality of life related to constipation

    Time frame: First postoperative week

    The investigators will evaluate BM quality based upon Bristol stool scale. Straining, abdominal or rectal pain, incomplete evacuation and the impact of these symptoms on GI-related quality of life will be assessed by the PAC-SYM and PAC-QOL validated questionnaires. The PAC-SYM is a validated 12-item questionnaire based upon the Rome criteria for constipation and is tailored to assess a change in symptoms following an intervention.2 This questionnaire has been previously used with success in studies with urogynecologic patients. The PAC-QOL is a validated 28-item questionnaire assessing quality-of-life issues, including burden of constipation on daily functioning and well-being. The Bristol stool scale, which is a visual BM rating scale from 1 to 7, provides a validated measure of gut transit time based upon the shape, consistency and appearance of BM.

  3. Symptoms of Over-Effectiveness

    Time frame: First Postoperative Week

    Symptoms of over-effectiveness, including abdominal pain or cramping, bloating, loose stools, watery diarrhea and their impact on GI-related quality of life will be evaluated based upon bowel diaries, Bristol stool scales and the PAC-SYM and PAC-QOL questionnaires.

  4. Evaluation of symptoms and quality of life related to constipation 6-weeks postoperatively

    Time frame: 5-7 weeks postoperatively

    The investigators will evaluate BM quality based upon Bristol stool scale. Straining, abdominal or rectal pain, incomplete evacuation and the impact of these symptoms on GI-related quality of life will be assessed by the PAC-SYM and PAC-QOL validated questionnaires. The PAC-SYM is a validated 12-item questionnaire based upon the Rome criteria for constipation and is tailored to assess a change in symptoms following an intervention.2 This questionnaire has been previously used with success in studies with urogynecologic patients. The PAC-QOL is a validated 28-item questionnaire assessing quality-of-life issues, including burden of constipation on daily functioning and well-being. The Bristol stool scale, which is a visual BM rating scale from 1 to 7, provides a validated measure of gut transit time based upon the shape, consistency and appearance of BM.

Sponsors and collaborators

Lead sponsor

Duke University

Other

Collaborators

  • American Urogynecologic Society

Registry information

Official study title

Double-Blind Randomized Controlled Trial of MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery in Women Receiving Routine Docusate Sodium

Acronym: MVP

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Sep 25, 2012
Registry last updated
Feb 15, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.